Is Codeine + Pseudoephedrine + Triprolidine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Codeine + Pseudoephedrine + Triprolidine.

Is Codeine + Pseudoephedrine + Triprolidine approved by the US FDA?

Drugs@FDA lists 4 application product lines for Codeine + Pseudoephedrine + Triprolidine, including TRIACIN-C (Prescription); TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE (Discontinued); TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE (Discontinued); ACTIFED W/ CODEINE (Discontinued).

Active substances

Codeine + Pseudoephedrine + Triprolidine

SFDA 1
US FDA 4
Health Canada 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ACTIFED COMPOUND LINCTUS	2, 6 , 0.25 mg/ml	Syrup · Oral use	1 Bottle	SAR 6.70	NCE · Prescription	GLAXOSMITHKLINE (GSK)	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
TRIACIN-C	10MG/5ML;30MG/5ML;1.25MG/5ML	syrup · oral	ANIMA	Prescription	22 Mar 1985
TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE	10MG/5ML;30MG/5ML;1.25MG/5ML	syrup · oral	WOCKHARDT	Discontinued	16 Nov 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE	10MG/5ML;30MG/5ML;1.25MG/5ML	syrup · oral	CENCI	Discontinued	23 Jul 1986
ACTIFED W/ CODEINE	10MG/5ML;30MG/5ML;1.25MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	syrup · oral	GLAXOSMITHKLINE	Discontinued

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
TEVA-COTRIDIN	02169126	10 MG / 5 ML; 2 MG / 5 ML; 30 MG / 5 ML	SYRUP · ORAL	TEVA CANADA LIMITED

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.